Last reviewed · How we verify
ID110521156
At a glance
| Generic name | ID110521156 |
|---|---|
| Sponsor | IlDong Pharmaceutical Co Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects (PHASE1)
- Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ID110521156 CI brief — competitive landscape report
- ID110521156 updates RSS · CI watch RSS
- IlDong Pharmaceutical Co Ltd portfolio CI